Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 175 EUR 3.8% Market Closed
Market Cap: 17B EUR
Have any thoughts about
Sartorius Stedim Biotech SA?
Write Note

Net Margin
Sartorius Stedim Biotech SA

6.2%
Current
17%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
6.2%
=
Net Income
169.2m
/
Revenue
2.7B

Net Margin Across Competitors

Country FR
Market Cap 17B EUR
Net Margin
6%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 196.3B USD
Net Margin
14%
Country US
Market Cap 170.3B USD
Net Margin
18%
Country KR
Market Cap 66.5T KRW
Net Margin
24%
Country CH
Market Cap 37.6B CHF
Net Margin
9%
Country US
Market Cap 38.5B USD
Net Margin
22%
Country US
Market Cap 36.7B USD
Net Margin
9%
Country US
Market Cap 26.4B USD
Net Margin
21%
Country US
Market Cap 23B USD
Net Margin
17%
Country US
Market Cap 22.3B USD
Net Margin
-36%
No Stocks Found

Sartorius Stedim Biotech SA
Glance View

Market Cap
17B EUR
Industry
Life Sciences Tools & Services

Sartorius Stedim Biotech SA, a key player in the biopharmaceutical industry, has positioned itself at the forefront of innovation in bioprocessing and laboratory solutions. Established in the early 2000s through the merger of Sartorius AG's biotech division and Stedim S.A., the company’s mission centers on enabling the development and production of life-saving biologics. With a comprehensive portfolio that includes bioprocessing equipment, research services, and laboratory instruments, Sartorius caters to a vast array of customers, from small biotech firms to large pharmaceuticals, ensuring seamless workflows in drug development and manufacturing. By leveraging cutting-edge technologies and maintaining a commitment to sustainability, Sartorius has built a reputation as a trusted partner in the industry, addressing the growing demand for effective therapies amidst an ever-evolving healthcare landscape. As the global biopharmaceutical market expands, driven by advancements in personalized medicine and precision therapies, Sartorius is well-positioned to capitalize on these trends. The company’s recent strategic acquisitions and investments in digitalization and automation enhance its product offerings, allowing clients to improve efficiencies and reduce time-to-market for essential therapeutics. Boasting a strong financial track record and a commitment to research and development, Sartorius Stedim Biotech SA not only ensures consistent growth but also aligns with long-term health sector trends. For investors, this combination of strategic vision, robust market position, and innovative capabilities makes Sartorius an attractive investment opportunity in the booming biotechnology sector.

DIM Intrinsic Value
159.09 EUR
Overvaluation 9%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
6.2%
=
Net Income
169.2m
/
Revenue
2.7B
What is the Net Margin of Sartorius Stedim Biotech SA?

Based on Sartorius Stedim Biotech SA's most recent financial statements, the company has Net Margin of 6.2%.